View DividendDIVA Laboratories マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報Chen Gene最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況お知らせ • Mar 02DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city TaiwanBoard Change • Oct 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ting-Hsuan Yu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Feb 27DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwanお知らせ • Jun 02DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration CommitteeDIVA Laboratories, Ltd. announced the change of Audit Committee and Remuneration Committee. Name of the previous position holder: Independent Director: Liu, Song-Ping. Resume of the previous position holder: Independent Director: Liu, Song-Ping Independent Director of DIVA Laboratories, Ltd. Name of the new position holder: Independent Director: You, Ting-Xuan. Resume of the new position holder: Independent Director: You, Ting-Xuan President of Teyu Innovation Investment Co., Ltd. Effective date of the new member is May 31, 2024.お知らせ • Jun 01DIVA Laboratories, Ltd. Announces Election of DirectorsDIVA Laboratories, Ltd. at its Annual General Shareholders' Meeting held on May 31, 2024, elected Huang, Han-Chu (Data Image Corporation Representative), Chen, Kuo-Sheng (Data Image Corporation Representative), Shiue, Tao-Lung (Data Image Corporation Representative), Yu, Szu-Ping (Data Image Corporation Representative), Yang, De-Sheng (Independent Director) and You, Ting-Xuan (Independent Director) as Directors.お知らせ • Mar 01DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024. Location: 10F., No.351, Sec. 2, Zhongshan Road, Zhonghe District Taipei City Taiwan Agenda: To Report of 2023 business; to Audit Committee's review report; to consider the 2023 Distribution of employees & board directors' remuneration; to consider the 2023 Distribution of 2023 profits in cash; to Capital reserve allocation and cash dividends; to accept the 2023 Business Report and Financial Statements; and to discuss other matters.すべての更新を表示Recent updatesNew Risk • Apr 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 140% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (NT$1.78b market cap, or US$56.5m).Reported Earnings • Apr 29First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$222.9m (up 7.6% from 1Q 2025). Net income: NT$24.8m (flat on 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 04Full year 2025 earnings released: EPS: NT$1.54 (vs NT$1.60 in FY 2024)Full year 2025 results: EPS: NT$1.54 (down from NT$1.60 in FY 2024). Revenue: NT$868.8m (flat on FY 2024). Net income: NT$90.5m (down 3.3% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Mar 02DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city TaiwanNew Risk • Nov 23New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 140% Cash payout ratio: 156% Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (NT$1.88b market cap, or US$60.0m).Reported Earnings • Oct 30Third quarter 2025 earnings released: EPS: NT$0.17 (vs NT$0.26 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.17 (down from NT$0.26 in 3Q 2024). Revenue: NT$197.0m (up 1.7% from 3Q 2024). Net income: NT$10.0m (down 33% from 3Q 2024). Profit margin: 5.1% (down from 7.8% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Board Change • Oct 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ting-Hsuan Yu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Sep 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 132% Cash payout ratio: 109% Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (NT$2.38b market cap, or US$77.8m).Reported Earnings • Jul 30Second quarter 2025 earnings released: EPS: NT$0.44 (vs NT$0.53 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.44 (down from NT$0.53 in 2Q 2024). Revenue: NT$235.0m (up 5.4% from 2Q 2024). Net income: NT$25.8m (down 17% from 2Q 2024). Profit margin: 11% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • May 30DIVA Laboratories, Ltd. Approves Cash Dividend, Payable on July 15, 2025DIVA Laboratories, Ltd. announced cash dividend of TWD 117,336,394 at TWD 2 per share (including by earnings distribution dividend at TWD 1.47648427 per share and the cash distribution from capital surplus at TWD 0.52351573 per share). Ex-rights (ex-dividend) date is June 13, 2025. Ex-rights (Ex-dividend) record date is June 21, 2025. Payment date of cash dividend distribution is July 15, 2025. Date of the resolution by the board of directors or shareholders’ meeting, or of the decision by the company is May 27, 2025.Declared Dividend • May 29Dividend increased to NT$2.00Dividend of NT$2.00 is 60% higher than last year. Ex-date: 13th June 2025 Payment date: 15th July 2025 Dividend yield will be 4.7%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not covered by earnings (125% earnings payout ratio) nor is it covered by cash flows (154% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 39% to bring the payout ratio under control, which is more than the 24% EPS growth achieved over the last 5 years.Reported Earnings • May 04First quarter 2025 earnings released: EPS: NT$0.42 (vs NT$0.41 in 1Q 2024)First quarter 2025 results: EPS: NT$0.42 (up from NT$0.41 in 1Q 2024). Revenue: NT$206.5m (down 7.1% from 1Q 2024). Net income: NT$24.9m (up 2.1% from 1Q 2024). Profit margin: 12% (up from 11% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 19DIVA Laboratories, Ltd. to Report Q1, 2025 Results on Apr 28, 2025DIVA Laboratories, Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$32.35, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 16x in the Electronic industry in Taiwan. Total returns to shareholders of 39% over the past three years.New Risk • Mar 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 125% Cash payout ratio: 97% Dividend yield: 5.1% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 125% Cash payout ratio: 97% Minor Risk Market cap is less than US$100m (NT$2.31b market cap, or US$69.6m).Reported Earnings • Mar 19Full year 2024 earnings released: EPS: NT$1.60 (vs NT$1.26 in FY 2023)Full year 2024 results: EPS: NT$1.60 (up from NT$1.26 in FY 2023). Revenue: NT$862.3m (down 3.5% from FY 2023). Net income: NT$93.7m (up 27% from FY 2023). Profit margin: 11% (up from 8.2% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 27DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwanお知らせ • Feb 19DIVA Laboratories, Ltd. to Report Q4, 2024 Results on Feb 26, 2025DIVA Laboratories, Ltd. announced that they will report Q4, 2024 results on Feb 26, 2025Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.26 (vs NT$0.33 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.26 (down from NT$0.33 in 3Q 2023). Revenue: NT$193.6m (down 6.6% from 3Q 2023). Net income: NT$15.1m (down 22% from 3Q 2023). Profit margin: 7.8% (down from 9.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 23DIVA Laboratories, Ltd. to Report Q3, 2024 Results on Oct 30, 2024DIVA Laboratories, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$0.20 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.52 (up from NT$0.20 in 2Q 2023). Revenue: NT$223.0m (down 4.2% from 2Q 2023). Net income: NT$31.0m (up 164% from 2Q 2023). Profit margin: 14% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 25DIVA Laboratories, Ltd. to Report Q2, 2024 Results on Aug 01, 2024DIVA Laboratories, Ltd. announced that they will report Q2, 2024 results on Aug 01, 2024Upcoming Dividend • Jun 12Upcoming dividend of NT$1.25 per shareEligible shareholders must have bought the stock before 19 June 2024. Payment date: 18 July 2024. Payout ratio is on the higher end at 96%, however this is supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (2.8%).お知らせ • Jun 02DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration CommitteeDIVA Laboratories, Ltd. announced the change of Audit Committee and Remuneration Committee. Name of the previous position holder: Independent Director: Liu, Song-Ping. Resume of the previous position holder: Independent Director: Liu, Song-Ping Independent Director of DIVA Laboratories, Ltd. Name of the new position holder: Independent Director: You, Ting-Xuan. Resume of the new position holder: Independent Director: You, Ting-Xuan President of Teyu Innovation Investment Co., Ltd. Effective date of the new member is May 31, 2024.お知らせ • Jun 01DIVA Laboratories, Ltd. Announces Election of DirectorsDIVA Laboratories, Ltd. at its Annual General Shareholders' Meeting held on May 31, 2024, elected Huang, Han-Chu (Data Image Corporation Representative), Chen, Kuo-Sheng (Data Image Corporation Representative), Shiue, Tao-Lung (Data Image Corporation Representative), Yu, Szu-Ping (Data Image Corporation Representative), Yang, De-Sheng (Independent Director) and You, Ting-Xuan (Independent Director) as Directors.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.42 (vs NT$0.36 in 1Q 2023)First quarter 2024 results: EPS: NT$0.42 (up from NT$0.36 in 1Q 2023). Revenue: NT$222.4m (down 11% from 1Q 2023). Net income: NT$24.4m (up 14% from 1Q 2023). Profit margin: 11% (up from 8.6% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 24DIVA Laboratories, Ltd. to Report Q1, 2024 Results on Apr 30, 2024DIVA Laboratories, Ltd. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on Apr 30, 2024Reported Earnings • Mar 22Full year 2023 earnings released: EPS: NT$1.25 (vs NT$0.85 in FY 2022)Full year 2023 results: EPS: NT$1.25 (up from NT$0.85 in FY 2022). Revenue: NT$893.8m (down 5.8% from FY 2022). Net income: NT$73.6m (up 48% from FY 2022). Profit margin: 8.2% (up from 5.2% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 01DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024. Location: 10F., No.351, Sec. 2, Zhongshan Road, Zhonghe District Taipei City Taiwan Agenda: To Report of 2023 business; to Audit Committee's review report; to consider the 2023 Distribution of employees & board directors' remuneration; to consider the 2023 Distribution of 2023 profits in cash; to Capital reserve allocation and cash dividends; to accept the 2023 Business Report and Financial Statements; and to discuss other matters.Reported Earnings • Nov 04Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.39 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.33 (down from NT$0.39 in 3Q 2022). Revenue: NT$207.2m (down 12% from 3Q 2022). Net income: NT$19.4m (down 14% from 3Q 2022). Profit margin: 9.4% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.059 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.20 (up from NT$0.059 in 2Q 2022). Revenue: NT$232.9m (up 3.6% from 2Q 2022). Net income: NT$11.7m (up 237% from 2Q 2022). Profit margin: 5.0% (up from 1.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$45.75, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 18x in the Electronic industry in Taiwan. Total returns to shareholders of 46% over the past three years.Upcoming Dividend • Jun 27Upcoming dividend of NT$1.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 04 August 2023. Payout ratio is on the higher end at 83%, however this is supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$46.00, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 14x in the Electronic industry in Taiwan. Total returns to shareholders of 52% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to NT$56.30, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 14x in the Electronic industry in Taiwan. Total returns to shareholders of 92% over the past three years.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: NT$0.85 (vs NT$0.37 in FY 2021)Full year 2022 results: EPS: NT$0.85 (up from NT$0.37 in FY 2021). Revenue: NT$949.2m (up 33% from FY 2021). Net income: NT$49.7m (up 127% from FY 2021). Profit margin: 5.2% (up from 3.1% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 05Third quarter 2022 earnings released: EPS: NT$0.39 (vs NT$0.27 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.39 (up from NT$0.27 in 3Q 2021). Revenue: NT$236.2m (up 18% from 3Q 2021). Net income: NT$22.6m (up 44% from 3Q 2021). Profit margin: 9.6% (up from 7.9% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: NT$0.06 (vs NT$0.11 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.06 (down from NT$0.11 in 2Q 2021). Revenue: NT$224.8m (up 34% from 2Q 2021). Net income: NT$3.49m (down 46% from 2Q 2021). Profit margin: 1.6% (down from 3.8% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 27Upcoming dividend of NT$0.37 per shareEligible shareholders must have bought the stock before 04 July 2022. Payment date: 03 August 2022. Payout ratio is on the higher end at 92% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Taiwanese dividend payers (6.3%). Lower than average of industry peers (4.6%).Reported Earnings • May 06First quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.002 in 1Q 2021)First quarter 2022 results: EPS: NT$0.03 (up from NT$0.002 in 1Q 2021). Revenue: NT$192.9m (up 28% from 1Q 2021). Net income: NT$1.86m (up NT$1.74m from 1Q 2021). Profit margin: 1.0% (up from 0.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 23DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022.Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$0.37 (up from NT$0.26 in FY 2020). Revenue: NT$712.2m (down 3.4% from FY 2020). Net income: NT$21.9m (up 26% from FY 2020). Profit margin: 3.1% (up from 2.4% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$0.37 (up from NT$0.26 in FY 2020). Revenue: NT$712.2m (down 3.4% from FY 2020). Net income: NT$21.9m (up 26% from FY 2020). Profit margin: 3.1% (up from 2.4% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.02 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: NT$200.6m (down 12% from 3Q 2020). Net income: NT$15.8m (up NT$14.5m from 3Q 2020). Profit margin: 7.9% (up from 0.6% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Nov 05Upcoming dividend of NT$0.26 per shareEligible shareholders must have bought the stock before 12 November 2021. Payment date: 15 December 2021. Trailing yield: 1.0%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (3.2%).Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$167.9m (down 19% from 2Q 2020). Net income: NT$6.39m (down 69% from 2Q 2020). Profit margin: 3.8% (down from 10% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$0.26 (vs NT$0.93 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$736.9m (up 2.9% from FY 2019). Net income: NT$17.4m (down 69% from FY 2019). Profit margin: 2.4% (down from 7.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.分析記事 • Feb 28Should You Be Impressed By DIVA Laboratories' (GTSM:4153) Returns on Capital?Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Is New 90 Day High Low • Feb 18New 90-day low: NT$22.85The company is down 17% from its price of NT$27.65 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 22% over the same period.Is New 90 Day High Low • Feb 03New 90-day low: NT$23.25The company is down 24% from its price of NT$30.45 on 05 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 24% over the same period.分析記事 • Dec 27DIVA Laboratories, Ltd. (GTSM:4153) Stock's On A Decline: Are Poor Fundamentals The Cause?With its stock down 17% over the past three months, it is easy to disregard DIVA Laboratories (GTSM:4153). To decide if...Is New 90 Day High Low • Dec 17New 90-day low: NT$23.90The company is down 30% from its price of NT$34.22 on 18 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: NT$26.60The company is down 1.0% from its price of NT$26.79 on 02 September 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 7.0% over the same period.分析記事 • Nov 30Is DIVA Laboratories (GTSM:4153) Likely To Turn Things Around?What are the early trends we should look for to identify a stock that could multiply in value over the long term...Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.02The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$228.9m (up 33% from 3Q 2019). Net income: NT$1.31m (down 90% from 3Q 2019). Profit margin: 0.6% (down from 7.5% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Upcoming Dividend • Oct 01Upcoming Dividend of NT$1.66 Per ShareWill be paid on the 26th of October to those who are registered shareholders by the 8th of October. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 3.9%.CEOChen Gene no data在職期間Chen Gene is Vice Chairman & CEO of DIVA Laboratories, Ltd. Chen Gene was Vice Chairman of DIVA Laboratories, Ltd.View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 13:34終値2026/05/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DIVA Laboratories, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Hsiu Chi LinMasterlink Securities Investment Advisory
お知らせ • Mar 02DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwan
Board Change • Oct 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ting-Hsuan Yu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Feb 27DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwan
お知らせ • Jun 02DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration CommitteeDIVA Laboratories, Ltd. announced the change of Audit Committee and Remuneration Committee. Name of the previous position holder: Independent Director: Liu, Song-Ping. Resume of the previous position holder: Independent Director: Liu, Song-Ping Independent Director of DIVA Laboratories, Ltd. Name of the new position holder: Independent Director: You, Ting-Xuan. Resume of the new position holder: Independent Director: You, Ting-Xuan President of Teyu Innovation Investment Co., Ltd. Effective date of the new member is May 31, 2024.
お知らせ • Jun 01DIVA Laboratories, Ltd. Announces Election of DirectorsDIVA Laboratories, Ltd. at its Annual General Shareholders' Meeting held on May 31, 2024, elected Huang, Han-Chu (Data Image Corporation Representative), Chen, Kuo-Sheng (Data Image Corporation Representative), Shiue, Tao-Lung (Data Image Corporation Representative), Yu, Szu-Ping (Data Image Corporation Representative), Yang, De-Sheng (Independent Director) and You, Ting-Xuan (Independent Director) as Directors.
お知らせ • Mar 01DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024. Location: 10F., No.351, Sec. 2, Zhongshan Road, Zhonghe District Taipei City Taiwan Agenda: To Report of 2023 business; to Audit Committee's review report; to consider the 2023 Distribution of employees & board directors' remuneration; to consider the 2023 Distribution of 2023 profits in cash; to Capital reserve allocation and cash dividends; to accept the 2023 Business Report and Financial Statements; and to discuss other matters.
New Risk • Apr 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 140% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (NT$1.78b market cap, or US$56.5m).
Reported Earnings • Apr 29First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$222.9m (up 7.6% from 1Q 2025). Net income: NT$24.8m (flat on 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 04Full year 2025 earnings released: EPS: NT$1.54 (vs NT$1.60 in FY 2024)Full year 2025 results: EPS: NT$1.54 (down from NT$1.60 in FY 2024). Revenue: NT$868.8m (flat on FY 2024). Net income: NT$90.5m (down 3.3% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Mar 02DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2026. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwan
New Risk • Nov 23New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 140% Cash payout ratio: 156% Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (NT$1.88b market cap, or US$60.0m).
Reported Earnings • Oct 30Third quarter 2025 earnings released: EPS: NT$0.17 (vs NT$0.26 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.17 (down from NT$0.26 in 3Q 2024). Revenue: NT$197.0m (up 1.7% from 3Q 2024). Net income: NT$10.0m (down 33% from 3Q 2024). Profit margin: 5.1% (down from 7.8% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Board Change • Oct 02Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ting-Hsuan Yu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Sep 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 132% Cash payout ratio: 109% Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (NT$2.38b market cap, or US$77.8m).
Reported Earnings • Jul 30Second quarter 2025 earnings released: EPS: NT$0.44 (vs NT$0.53 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.44 (down from NT$0.53 in 2Q 2024). Revenue: NT$235.0m (up 5.4% from 2Q 2024). Net income: NT$25.8m (down 17% from 2Q 2024). Profit margin: 11% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • May 30DIVA Laboratories, Ltd. Approves Cash Dividend, Payable on July 15, 2025DIVA Laboratories, Ltd. announced cash dividend of TWD 117,336,394 at TWD 2 per share (including by earnings distribution dividend at TWD 1.47648427 per share and the cash distribution from capital surplus at TWD 0.52351573 per share). Ex-rights (ex-dividend) date is June 13, 2025. Ex-rights (Ex-dividend) record date is June 21, 2025. Payment date of cash dividend distribution is July 15, 2025. Date of the resolution by the board of directors or shareholders’ meeting, or of the decision by the company is May 27, 2025.
Declared Dividend • May 29Dividend increased to NT$2.00Dividend of NT$2.00 is 60% higher than last year. Ex-date: 13th June 2025 Payment date: 15th July 2025 Dividend yield will be 4.7%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not covered by earnings (125% earnings payout ratio) nor is it covered by cash flows (154% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 39% to bring the payout ratio under control, which is more than the 24% EPS growth achieved over the last 5 years.
Reported Earnings • May 04First quarter 2025 earnings released: EPS: NT$0.42 (vs NT$0.41 in 1Q 2024)First quarter 2025 results: EPS: NT$0.42 (up from NT$0.41 in 1Q 2024). Revenue: NT$206.5m (down 7.1% from 1Q 2024). Net income: NT$24.9m (up 2.1% from 1Q 2024). Profit margin: 12% (up from 11% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 19DIVA Laboratories, Ltd. to Report Q1, 2025 Results on Apr 28, 2025DIVA Laboratories, Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$32.35, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 16x in the Electronic industry in Taiwan. Total returns to shareholders of 39% over the past three years.
New Risk • Mar 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 125% Cash payout ratio: 97% Dividend yield: 5.1% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 125% Cash payout ratio: 97% Minor Risk Market cap is less than US$100m (NT$2.31b market cap, or US$69.6m).
Reported Earnings • Mar 19Full year 2024 earnings released: EPS: NT$1.60 (vs NT$1.26 in FY 2023)Full year 2024 results: EPS: NT$1.60 (up from NT$1.26 in FY 2023). Revenue: NT$862.3m (down 3.5% from FY 2023). Net income: NT$93.7m (up 27% from FY 2023). Profit margin: 11% (up from 8.2% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 27DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025DIVA Laboratories, Ltd., Annual General Meeting, May 27, 2025. Location: 10 floor no,351, sec.2 chung shan rd., jhonghe district, new taipei city Taiwan
お知らせ • Feb 19DIVA Laboratories, Ltd. to Report Q4, 2024 Results on Feb 26, 2025DIVA Laboratories, Ltd. announced that they will report Q4, 2024 results on Feb 26, 2025
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.26 (vs NT$0.33 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.26 (down from NT$0.33 in 3Q 2023). Revenue: NT$193.6m (down 6.6% from 3Q 2023). Net income: NT$15.1m (down 22% from 3Q 2023). Profit margin: 7.8% (down from 9.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 23DIVA Laboratories, Ltd. to Report Q3, 2024 Results on Oct 30, 2024DIVA Laboratories, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$0.20 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.52 (up from NT$0.20 in 2Q 2023). Revenue: NT$223.0m (down 4.2% from 2Q 2023). Net income: NT$31.0m (up 164% from 2Q 2023). Profit margin: 14% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 25DIVA Laboratories, Ltd. to Report Q2, 2024 Results on Aug 01, 2024DIVA Laboratories, Ltd. announced that they will report Q2, 2024 results on Aug 01, 2024
Upcoming Dividend • Jun 12Upcoming dividend of NT$1.25 per shareEligible shareholders must have bought the stock before 19 June 2024. Payment date: 18 July 2024. Payout ratio is on the higher end at 96%, however this is supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (2.8%).
お知らせ • Jun 02DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration CommitteeDIVA Laboratories, Ltd. announced the change of Audit Committee and Remuneration Committee. Name of the previous position holder: Independent Director: Liu, Song-Ping. Resume of the previous position holder: Independent Director: Liu, Song-Ping Independent Director of DIVA Laboratories, Ltd. Name of the new position holder: Independent Director: You, Ting-Xuan. Resume of the new position holder: Independent Director: You, Ting-Xuan President of Teyu Innovation Investment Co., Ltd. Effective date of the new member is May 31, 2024.
お知らせ • Jun 01DIVA Laboratories, Ltd. Announces Election of DirectorsDIVA Laboratories, Ltd. at its Annual General Shareholders' Meeting held on May 31, 2024, elected Huang, Han-Chu (Data Image Corporation Representative), Chen, Kuo-Sheng (Data Image Corporation Representative), Shiue, Tao-Lung (Data Image Corporation Representative), Yu, Szu-Ping (Data Image Corporation Representative), Yang, De-Sheng (Independent Director) and You, Ting-Xuan (Independent Director) as Directors.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.42 (vs NT$0.36 in 1Q 2023)First quarter 2024 results: EPS: NT$0.42 (up from NT$0.36 in 1Q 2023). Revenue: NT$222.4m (down 11% from 1Q 2023). Net income: NT$24.4m (up 14% from 1Q 2023). Profit margin: 11% (up from 8.6% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 24DIVA Laboratories, Ltd. to Report Q1, 2024 Results on Apr 30, 2024DIVA Laboratories, Ltd. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on Apr 30, 2024
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: NT$1.25 (vs NT$0.85 in FY 2022)Full year 2023 results: EPS: NT$1.25 (up from NT$0.85 in FY 2022). Revenue: NT$893.8m (down 5.8% from FY 2022). Net income: NT$73.6m (up 48% from FY 2022). Profit margin: 8.2% (up from 5.2% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 01DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024. Location: 10F., No.351, Sec. 2, Zhongshan Road, Zhonghe District Taipei City Taiwan Agenda: To Report of 2023 business; to Audit Committee's review report; to consider the 2023 Distribution of employees & board directors' remuneration; to consider the 2023 Distribution of 2023 profits in cash; to Capital reserve allocation and cash dividends; to accept the 2023 Business Report and Financial Statements; and to discuss other matters.
Reported Earnings • Nov 04Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.39 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.33 (down from NT$0.39 in 3Q 2022). Revenue: NT$207.2m (down 12% from 3Q 2022). Net income: NT$19.4m (down 14% from 3Q 2022). Profit margin: 9.4% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.059 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.20 (up from NT$0.059 in 2Q 2022). Revenue: NT$232.9m (up 3.6% from 2Q 2022). Net income: NT$11.7m (up 237% from 2Q 2022). Profit margin: 5.0% (up from 1.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$45.75, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 18x in the Electronic industry in Taiwan. Total returns to shareholders of 46% over the past three years.
Upcoming Dividend • Jun 27Upcoming dividend of NT$1.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 04 August 2023. Payout ratio is on the higher end at 83%, however this is supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$46.00, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 14x in the Electronic industry in Taiwan. Total returns to shareholders of 52% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to NT$56.30, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 14x in the Electronic industry in Taiwan. Total returns to shareholders of 92% over the past three years.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: NT$0.85 (vs NT$0.37 in FY 2021)Full year 2022 results: EPS: NT$0.85 (up from NT$0.37 in FY 2021). Revenue: NT$949.2m (up 33% from FY 2021). Net income: NT$49.7m (up 127% from FY 2021). Profit margin: 5.2% (up from 3.1% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 05Third quarter 2022 earnings released: EPS: NT$0.39 (vs NT$0.27 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.39 (up from NT$0.27 in 3Q 2021). Revenue: NT$236.2m (up 18% from 3Q 2021). Net income: NT$22.6m (up 44% from 3Q 2021). Profit margin: 9.6% (up from 7.9% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 05Second quarter 2022 earnings released: EPS: NT$0.06 (vs NT$0.11 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.06 (down from NT$0.11 in 2Q 2021). Revenue: NT$224.8m (up 34% from 2Q 2021). Net income: NT$3.49m (down 46% from 2Q 2021). Profit margin: 1.6% (down from 3.8% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 27Upcoming dividend of NT$0.37 per shareEligible shareholders must have bought the stock before 04 July 2022. Payment date: 03 August 2022. Payout ratio is on the higher end at 92% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Taiwanese dividend payers (6.3%). Lower than average of industry peers (4.6%).
Reported Earnings • May 06First quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.002 in 1Q 2021)First quarter 2022 results: EPS: NT$0.03 (up from NT$0.002 in 1Q 2021). Revenue: NT$192.9m (up 28% from 1Q 2021). Net income: NT$1.86m (up NT$1.74m from 1Q 2021). Profit margin: 1.0% (up from 0.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 23DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022.
Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$0.37 (up from NT$0.26 in FY 2020). Revenue: NT$712.2m (down 3.4% from FY 2020). Net income: NT$21.9m (up 26% from FY 2020). Profit margin: 3.1% (up from 2.4% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$0.37 (up from NT$0.26 in FY 2020). Revenue: NT$712.2m (down 3.4% from FY 2020). Net income: NT$21.9m (up 26% from FY 2020). Profit margin: 3.1% (up from 2.4% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.02 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: NT$200.6m (down 12% from 3Q 2020). Net income: NT$15.8m (up NT$14.5m from 3Q 2020). Profit margin: 7.9% (up from 0.6% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Nov 05Upcoming dividend of NT$0.26 per shareEligible shareholders must have bought the stock before 12 November 2021. Payment date: 15 December 2021. Trailing yield: 1.0%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (3.2%).
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$167.9m (down 19% from 2Q 2020). Net income: NT$6.39m (down 69% from 2Q 2020). Profit margin: 3.8% (down from 10% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$0.26 (vs NT$0.93 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$736.9m (up 2.9% from FY 2019). Net income: NT$17.4m (down 69% from FY 2019). Profit margin: 2.4% (down from 7.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
分析記事 • Feb 28Should You Be Impressed By DIVA Laboratories' (GTSM:4153) Returns on Capital?Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Is New 90 Day High Low • Feb 18New 90-day low: NT$22.85The company is down 17% from its price of NT$27.65 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 22% over the same period.
Is New 90 Day High Low • Feb 03New 90-day low: NT$23.25The company is down 24% from its price of NT$30.45 on 05 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 24% over the same period.
分析記事 • Dec 27DIVA Laboratories, Ltd. (GTSM:4153) Stock's On A Decline: Are Poor Fundamentals The Cause?With its stock down 17% over the past three months, it is easy to disregard DIVA Laboratories (GTSM:4153). To decide if...
Is New 90 Day High Low • Dec 17New 90-day low: NT$23.90The company is down 30% from its price of NT$34.22 on 18 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: NT$26.60The company is down 1.0% from its price of NT$26.79 on 02 September 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 7.0% over the same period.
分析記事 • Nov 30Is DIVA Laboratories (GTSM:4153) Likely To Turn Things Around?What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.02The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$228.9m (up 33% from 3Q 2019). Net income: NT$1.31m (down 90% from 3Q 2019). Profit margin: 0.6% (down from 7.5% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Oct 01Upcoming Dividend of NT$1.66 Per ShareWill be paid on the 26th of October to those who are registered shareholders by the 8th of October. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 3.9%.